Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Recce Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.85M | 4.37M | 3.08M | 1.64M | 1.12M |
| Gross Profit | -366.77K | 4.15M | 2.90M | 1.34M | 920.91K |
| EBITDA | -21.35M | -16.99M | -10.80M | -14.77M | -5.13M |
| Net Income | -17.66M | -13.08M | -10.99M | -13.51M | -4.32M |
Balance Sheet | |||||
| Total Assets | 6.37M | 2.56M | 12.62M | 21.68M | 3.24M |
| Cash, Cash Equivalents and Short-Term Investments | 4.42M | 1.56M | 11.58M | 20.87M | 2.68M |
| Total Debt | 811.19K | 250.57K | 74.76K | 126.95K | 83.23K |
| Total Liabilities | 15.89M | 5.14M | 2.56M | 1.18M | 931.53K |
| Stockholders Equity | -9.52M | -2.59M | 10.06M | 20.50M | 2.31M |
Cash Flow | |||||
| Free Cash Flow | -13.15M | -12.73M | -9.05M | -7.93M | -3.81M |
| Operating Cash Flow | -13.01M | -12.69M | -9.01M | -7.86M | -3.81M |
| Investing Cash Flow | -141.90K | -38.63K | -40.34K | -76.01K | -5.94K |
| Financing Cash Flow | 16.00M | 2.71M | -240.50K | 26.12M | 6.09M |
Recce Pharmaceuticals Ltd. Technical Analysis
Recce Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.36B | -0.07 | -63.77% | 2.36% | 16.35% | 0.03% | |
40 Underperform | AU$99.77M | ― | ― | ― | -33.01% | ||
| ― | $72.46M | ― | -41.60% | ― | ― | ― | |
| ― | $53.90M | ― | -99.05% | ― | ― | ― | |
| ― | $90.34M | ― | -154.88% | ― | ― | ― | |
56 Neutral | AU$37.85M | ― | -36.95% | ― | ― | 11.11% | |
40 Underperform | AU$124.80M | ― | -85.35% | ― | 315.11% | 51.16% |
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals Ltd announced the issuance of 811,062 fully paid ordinary shares without disclosure to investors under the Corporations Act. This move aligns with the company’s compliance with relevant legal provisions and does not involve any excluded information. The issuance of new shares is part of Recce’s ongoing efforts to support its operations and clinical trials, enhancing its position in the pharmaceutical industry focused on addressing unmet medical needs related to antibiotic resistance.
Recce Pharmaceuticals Ltd has announced the application for quotation of 811,062 fully paid ordinary shares on the ASX. These shares were issued as part of compensation for services provided to the company, including legal, corporate advisory, investor relations, and stakeholder engagement support. This move is expected to enhance the company’s financial flexibility and strengthen its operational capabilities, potentially impacting its market position positively.
Recce Pharmaceuticals Ltd announced a proposed issue of securities, including warrants and ordinary shares, set to be issued by the end of 2025. This strategic move aims to bolster the company’s financial resources, potentially enhancing its market position and operational capabilities in the pharmaceutical sector.
Recce Pharmaceuticals has secured a non-dilutive debt facility of up to A$30 million with Avenue Capital Group, providing initial funding of A$11.5 million to support Phase 3 clinical trials and commercialization efforts for its lead candidate R327G. This financial move, alongside a recent equity raise, strengthens Recce’s cash position, ensuring a cash runway sufficient for trial completion and market authorization submissions. The partnership with Avenue Capital Group underscores the commercial potential of Recce’s synthetic anti-infectives and their role in addressing antimicrobial resistance, marking a significant step in the company’s growth and strategic objectives.
FIL Limited has increased its stake in Recce Pharmaceuticals Ltd., raising its voting power from 6.40% to 8.57% by acquiring an additional 7,950,744 common shares. This change in substantial holding reflects a growing confidence in Recce Pharmaceuticals’ strategic direction and potential, potentially impacting the company’s market positioning and stakeholder interests positively.
Recce Pharmaceuticals Ltd. has announced a change in the substantial holding of its shares, with Gavin William Brown increasing his voting power from 7.16% to 12.39% through the acquisition of shortfall shares from the company’s recent entitlement offer. This change in shareholding could potentially impact the company’s governance and strategic decisions, reflecting increased investor confidence in Recce Pharmaceuticals’ market positioning and future prospects.
Recce Pharmaceuticals Ltd announced the issuance of 26,370,567 fully paid ordinary shares, raising A$7.4 million through a pro-rata non-renounceable entitlement offer. The company is also negotiating a secured loan facility with a US-based investment firm for up to USD $20 million to refinance existing debt and provide working capital. This financial maneuvering reflects Recce’s strategic efforts to strengthen its financial position and support its ongoing development of innovative anti-infective solutions, potentially impacting its market positioning and stakeholder interests.
Recce Pharmaceuticals Ltd has announced the application for the quotation of 26,370,567 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 10, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence, potentially increasing its visibility and accessibility to investors, thereby supporting its strategic growth initiatives in the pharmaceutical sector.
Recce Pharmaceuticals Ltd has successfully completed a capital raising of A$15.8 million, including a shortfall placement of approximately 26.4 million shares to existing institutional and sophisticated investors, raising A$7.4 million. The funds will support significant Phase 3 clinical trials for topical treatments in Indonesia and Australia, aiming for commercialization and an Investigational New Drug Application to the US FDA. This capital raising marks a crucial step for Recce as it progresses towards establishing a new standard of care in infectious diseases, potentially improving patient outcomes and enhancing the company’s market position.
Recce Pharmaceuticals Ltd. has received a Notice of Acceptance from the China National Intellectual Property Administration for its patent on anti-infectives, extending its patent portfolio to the world’s second-largest pharmaceutical market. This development is significant as it validates Recce’s innovative treatments for various infections and enhances its market positioning, potentially benefiting stakeholders by tapping into a growing Chinese antibiotic market projected to expand at a CAGR of 5.7% from 2025 to 2030.
FIL Limited has increased its stake in Recce Pharmaceuticals Ltd., now holding 16,755,072 shares, which represents a 6.40% voting power in the company. This change in substantial holding reflects FIL Limited’s continued investment in Recce Pharmaceuticals, potentially signaling confidence in the company’s strategic direction and its innovative approach to tackling antibiotic resistance, which could have significant implications for stakeholders and the broader pharmaceutical industry.
Recce Pharmaceuticals Ltd announced a change in the director’s interest, with Dr. John Prendergast acquiring 51,136 fully paid ordinary shares through participation in the company’s pro-rata non-renounceable entitlement offer. This acquisition reflects an increase in Dr. Prendergast’s holdings, potentially signaling confidence in the company’s strategic direction and financial health, which may positively influence stakeholder perception and market positioning.
Recce Pharmaceuticals Ltd. successfully completed an entitlement offer, raising approximately A$3.4 million from existing shareholders, contributing to a total of A$8.4 million raised including a previous placement. This funding will support Phase 3 clinical trials for Diabetic Foot Infection in Indonesia and Acute Bacterial Skin and Skin Structure Infections in Australia, with an aim for commercialization and revenue generation by 2026. The company expressed gratitude towards its shareholders for their support and highlighted the importance of these trials as a catalyst for future revenue.
Recce Pharmaceuticals Ltd has announced the quotation of 12,273,033 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 16, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial position, potentially impacting its market presence and stakeholder interests positively.
Recce Pharmaceuticals Ltd announced the receipt of a US$175,122 rebate from the Canadian Government under the SR&ED Tax Incentive program, which supports R&D activities in Canada. This rebate complements the Australian government’s R&D Tax Incentive, highlighting Recce’s expanding research efforts and the international support for their innovative anti-infective developments.
Recce Pharmaceuticals Ltd has announced an update to its previous announcement regarding the proposed issue of securities. The company has revised the dates for the offer closing, trading commencement on a deferred settlement basis, and the issue date, among others. This update is crucial for stakeholders as it outlines the timeline for the securities offering, which could impact the company’s financial strategy and market positioning.
Recce Pharmaceuticals Ltd has announced an extension of the closing date for its pro-rata non-renounceable entitlement offer, allowing eligible shareholders more time to participate. The offer aims to raise up to $10.8 million and provides an opportunity for shareholders to apply for additional shares under the shortfall offer, potentially impacting the company’s financial position and market operations.
Recce Pharmaceuticals has entered into a Cooperative Research and Development Agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), supported by the Defense Threat Reduction Agency. This agreement will involve testing Recce’s synthetic anti-infective, RECCE 327, against biodefense pathogens in USAMRIID’s high biocontainment facilities. This partnership complements a recent US$2 million grant from the U.S. Department of Defense for a burn wound program, enhancing Recce’s collaboration with U.S. Government initiatives and potentially advancing the development of R327 as a treatment for severe infections.
Recce Pharmaceuticals Ltd announced the availability of a recording from their recent investor webinar, where company executives discussed updates on clinical activities and the outlook for upcoming Phase 3 trials. They also detailed a recent AUD ~$15.8 million Placement and Entitlement Offer, which will support their clinical activities as they move towards commercialization in 2026.
Recce Pharmaceuticals Ltd has announced a pro-rata non-renounceable entitlement offer to raise approximately $10.8 million, aimed at funding Phase III clinical trials and other development programs. The offer is available to eligible shareholders in specific regions, while ineligible shareholders have been notified of their exclusion due to cost and regulatory considerations. The funds will support trials in Indonesia and Australia, as well as additional clinical activities and working capital, positioning the company for potential revenue generation in 2026.
Recce Pharmaceuticals Ltd. has announced the opening of a pro-rata non-renounceable entitlement offer, allowing eligible shareholders to purchase one new share for every six shares held at an issue price of $0.28 per share. This offer aims to raise approximately $10.8 million before costs, with the funds potentially enhancing the company’s operational capabilities and market position.
Recce Pharmaceuticals Ltd. has received Human Research Ethics Committee approval to expand its Phase II clinical trial for the RECCE® 327 Topical Gel, allowing up to 20 additional diabetic patients with foot infections to participate. This decision follows promising Phase II results, where the gel showed high efficacy in treating acute bacterial skin and skin-structure infections, including diabetic foot ulcer infections. The study aims to address the urgent need for effective treatments, as diabetic foot infections have high recurrence rates and can lead to severe complications. The trial will run alongside Recce’s Phase 3 programs in Indonesia and Australia, further supporting the company’s clinical momentum and data portfolio.